Literature DB >> 6199132

Phase-II study of cis-diammine-dichloro platinum (cis-platinum), bleomycin and methotrexate for advanced squamous cell carcinoma of head and neck.

P Espana, F Smith, J Abrams, D Haidak, W Ueno, P Woolley, P Schein.   

Abstract

Twenty-one patients with head and neck carcinomas relapsing after radiotherapy were treated with a combination of cis-platinum, bleomycin, and methotrexate. Four patients (19%) achieved a partial response. Toxicity was significant in selected cases; three patients developed WBC counts less than 1,000/mm3 and one of these patients died with sepsis. Severe mucositis was present in three of the twenty-one patients. Considering the toxicity of this combination and the limited therapeutic activity with the dose and schedule used in this study, this regimen is not recommended for the treatment of squamous head and neck carcinomas relapsing after radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199132     DOI: 10.1007/bf00254598

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue.

Authors:  S W Pitman; D Miller; R Weichselbaum
Journal:  Laryngoscope       Date:  1978-04       Impact factor: 3.325

2.  Improved results in combination chemotherapy of head and neck cancer using a kinetically-based approach: a randomised study with and without adriamycin.

Authors:  L A Price; B T Hill; A H Calvert; M Dalley; A Levene; E R Busby; M Schachter; H J Shaw
Journal:  Oncology       Date:  1978       Impact factor: 2.935

3.  Improved therapeutic index of bleomycin when administered by continuous infusion in mice.

Authors:  B I Sikic; J M Collins; E G Mimnaugh; T E Gram
Journal:  Cancer Treat Rep       Date:  1978-12

Review 4.  Investigational chemotherapeutic agents in head and neck cancer.

Authors:  M Rozencweig; D D Von Hoff; F M Muggia
Journal:  Semin Oncol       Date:  1977-12       Impact factor: 4.929

5.  The role of chemotherapy in the management of cancer of the head and neck: a review.

Authors:  J R Bertino; B Boston; R L Capizzi
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

6.  Chemotherapy for head and neck cancer relapsing after radiotherapy.

Authors:  E P Cortes; J Kalra; V C Amin; J Attie; L Eisenbud; R Khafif; D Wolk; I Aral; J Sciubba; N Akbiyik; K Heller
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860

7.  The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study.

Authors:  J H Glick; V Marcial; M Richter; E Velez-Garcia
Journal:  Cancer       Date:  1980-11-01       Impact factor: 6.860

8.  Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion.

Authors:  W K Hong; S M Shapshay; R Bhutani; M L Craft; A Ucmakli; K T Yamaguchi; C W Vaughan; M S Strong
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

9.  Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy.

Authors:  V L Randolph; A Vallejo; R H Spiro; J Shah; E W Strong; A G Huvos; R E Wittes
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

10.  Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration.

Authors:  Y M Peng; D S Alberts; H S Chen; N Mason; T E Moon
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.